AI
AVTX icon

Allostery Investments’s Avalo Therapeutics AVTX Stock Holding History

Allostery Investments’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,000
Closed -$44.9K – 6
2025
Q2 		$44.9K Sell
9,000
-98,141
-92% -$458K 0.57% 20
2025
Q1 		$858K Buy
107,141
+33,827
+46% +$256K 1.24% 20
2024
Q4 		$545K Buy
+73,314
New +$784K 0.57% 28

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Allostery Investments's AVTX Position: Q3 2025 in Review

Allostery Investments sold out of Avalo Therapeutics (AVTX) in Q3 2025, closing a stake of 9,000 shares — an estimated $44.9K sold.

Allostery Investments first reported a position in AVTX in Q4 2024 and held it in 3 quarters. The position peaked at $858K in Q1 2025. 66 funds tracked by Wall St. Rank hold AVTX as of Q3 2025.

  • Allostery Investments reported no remaining Avalo Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Allostery Investments sold 9,000 Avalo Therapeutics shares in Q3 2025, an estimated $44.9K.
  • Allostery Investments first reported a position in Avalo Therapeutics in Q4 2024 and held it in 3 quarters.
  • Allostery Investments's Avalo Therapeutics position peaked at $858K in Q1 2025.
  • 66 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.